These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19804694)

  • 1. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 1.
    Bremmer M; Deng A; Gaspari AA
    Dermatitis; 2009; 20(4):182-92. PubMed ID: 19804694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2.
    Bremmer M; Deng A; Gaspari AA
    Dermatitis; 2009; 20(5):243-56. PubMed ID: 19807998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy.
    Ladizinski B; Heller MM; Bhutani T; Zitelli KB; Koo JY
    J Drugs Dermatol; 2013 Feb; 12(2):e20-4. PubMed ID: 23377400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cutaneous adverse effects of TNFalpha antagonists].
    Failla V; Sabatiello M; Lebas E; de Schaetzen V; Dezfoulian B; Nikkels AF
    Rev Med Liege; 2012; 67 Spec No():3-7. PubMed ID: 22690479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Biologic Therapies in Dermatology.
    Fathi R; Armstrong AW
    Med Clin North Am; 2015 Nov; 99(6):1183-94. PubMed ID: 26476247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications and adverse reactions in the use of newer biologic agents.
    Callen JP
    Semin Cutan Med Surg; 2007 Mar; 26(1):6-14. PubMed ID: 17349557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic therapies in dermatology.
    Chularojanamontri L; Griffiths CE
    Br J Hosp Med (Lond); 2013 Jan; 74(1):12-7. PubMed ID: 23593668
    [No Abstract]   [Full Text] [Related]  

  • 9. Biologics in dermatology: adverse effects.
    Sehgal VN; Pandhi D; Khurana A
    Int J Dermatol; 2015 Dec; 54(12):1442-60. PubMed ID: 26147909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.
    Smith CH; Anstey AV; Barker JN; Burden AD; Chalmers RJ; Chandler DA; Finlay AY; Griffiths CE; Jackson K; McHugh NJ; McKenna KE; Reynolds NJ; Ormerod AD;
    Br J Dermatol; 2009 Nov; 161(5):987-1019. PubMed ID: 19857207
    [No Abstract]   [Full Text] [Related]  

  • 13. Pigmented lichenoid drug eruption: a new clinical presentation of interface dermatitis induced by anti-TNF alpha drugs.
    Darrigade AS; Goussot JF; Milpied B; Taieb A; Seneschal J
    Eur J Dermatol; 2016 Dec; 26(6):633-634. PubMed ID: 27634463
    [No Abstract]   [Full Text] [Related]  

  • 14. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.
    Hawryluk EB; Linskey KR; Duncan LM; Nazarian RM
    J Cutan Pathol; 2012 May; 39(5):481-92. PubMed ID: 22515220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adverse events during biological therapy -- focusing on dermatological side-effects].
    Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z
    Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists.
    Asarch A; Gottlieb AB; Lee J; Masterpol KS; Scheinman PL; Stadecker MJ; Massarotti EM; Bush ML
    J Am Acad Dermatol; 2009 Jul; 61(1):104-11. PubMed ID: 19539844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The dermocorticoids, irreplaceable and feared].
    Zenklusen C; Feldmeyer L
    Rev Med Suisse; 2014 Apr; 10(425):821-6. PubMed ID: 24791429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
    Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
    Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label uses of biologic agents in dermatology: a 2006 update.
    Kerns MJ; Graves JE; Smith DI; Heffernan MP
    Semin Cutan Med Surg; 2006 Dec; 25(4):226-40. PubMed ID: 17174843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.